Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 616 participants.

Also called NCT02021318

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 616 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02021318
  • EudraCT 2013-000951-42
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Austria, Belarus, Bulgaria, Croatia, Czechia, Finland, France, Georgia, Germany, Hungary, Ireland, Israel, Latvia, Montenegro, Netherlands, North Macedonia, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02021318. Randomized; no masking; primary purpose treatment. Start 2014-03-12 (actual); primary completion 2018-03-23 (actual). Results posted on 2021-03-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa
Acronym
Dolomites
Condition
Anemia in Chronic Kidney Disease in Non-dialysis Patients
Intervention (Drug)
Roxadustat
Intervention (Drug)
Darbepoetin alfa
Lead sponsor
Astellas Pharma Europe B.V. (class: industry)
Collaborator
Kyntra Bio (class: industry)

Record details

Record id
cardio:ct-nct02021318
Content hash
51fc56e9c8e36cb60da9c40cb9a6302af9f14ad22f1a24c8afc8b57cd3f6fced